These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 21317877)
1. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Koh YW; Lee HJ; Lee JW; Kang J; Gong G Mod Pathol; 2011 Jun; 24(6):794-800. PubMed ID: 21317877 [TBL] [Abstract][Full Text] [Related]
2. Determination of HER2 gene amplification in breast cancer using dual-color silver enhanced in situ hybridization (dc- SISH) and comparison with fluorescence ISH (FISH). Unal B; Karaveli FS; Pestereli HE; Erdogan G Asian Pac J Cancer Prev; 2013; 14(10):6131-4. PubMed ID: 24289638 [TBL] [Abstract][Full Text] [Related]
3. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Francis GD; Jones MA; Beadle GF; Stein SR Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296 [TBL] [Abstract][Full Text] [Related]
4. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens. Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950 [TBL] [Abstract][Full Text] [Related]
6. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH). Fritzsche FR; Bode PK; Moch H; Kristiansen G; Varga Z; Bode B Am J Surg Pathol; 2010 Aug; 34(8):1180-5. PubMed ID: 20661016 [TBL] [Abstract][Full Text] [Related]
7. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074 [TBL] [Abstract][Full Text] [Related]
8. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. Jacquemier J; Spyratos F; Esterni B; Mozziconacci MJ; Antoine M; Arnould L; Lizard S; Bertheau P; Lehmann-Che J; Fournier CB; Krieger S; Bibeau F; Lamy PJ; Chenard MP; Legrain M; Guinebretière JM; Loussouarn D; Macgrogan G; Hostein I; Mathieu MC; Lacroix L; Valent A; Robin YM; Revillion F; Triki ML; Seaume A; Salomon AV; de Cremoux P; Portefaix G; Xerri L; Vacher S; Bièche I; Penault-Llorca F BMC Cancer; 2013 Jul; 13():351. PubMed ID: 23875536 [TBL] [Abstract][Full Text] [Related]
9. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. García-García E; Gómez-Martín C; Angulo B; Conde E; Suárez-Gauthier A; Adrados M; Perna C; Rodríguez-Peralto JL; Hidalgo M; López-Ríos F Histopathology; 2011 Jul; 59(1):8-17. PubMed ID: 21771023 [TBL] [Abstract][Full Text] [Related]
10. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization. Lim SJ; Cantillep A; Carpenter PM Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600 [TBL] [Abstract][Full Text] [Related]
11. Comparison of HER2 status determination methods in HER2 (2+) patients: Manual fluorescent in situ hybridization (FISH) vs. dual silver enhanced in situ hybridization (SISH). Pehlivanoglu B; Serin G; Yeniay L; Zekioglu O; Gokmen E; Ozdemir N Ann Diagn Pathol; 2017 Dec; 31():36-40. PubMed ID: 29146056 [TBL] [Abstract][Full Text] [Related]
12. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study. Lee Y; Ryu Y; Jeong H; Chang H; Kim Y; Kim A Arch Med Res; 2012 Feb; 43(2):139-44. PubMed ID: 22475781 [TBL] [Abstract][Full Text] [Related]
14. HER2 status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhanced in situ hybridization (SISH). Thang VH; Tani E; Van TT; Krawiec K; Skoog L Acta Oncol; 2011 Apr; 50(3):360-6. PubMed ID: 21338271 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114 [TBL] [Abstract][Full Text] [Related]
16. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization]. Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811 [TBL] [Abstract][Full Text] [Related]
17. [Dual-color silver-enhanced in-situ hybridization and fluorescence in-situ hybridization for determination of HER2 gene status in gastric carcinoma]. Long XY; Bu H; Wei B; Liu XY; Chen M; Chen J; Liu JP Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):300-3. PubMed ID: 21756822 [TBL] [Abstract][Full Text] [Related]
18. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. García-Caballero T; Grabau D; Green AR; Gregory J; Schad A; Kohlwes E; Ellis IO; Watts S; Mollerup J Histopathology; 2010 Mar; 56(4):472-80. PubMed ID: 20459554 [TBL] [Abstract][Full Text] [Related]
19. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer. Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH). Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]